Ovarian Cancer

The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.

PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.

The combination of paclitaxel and the angiogenesis inhibitor trebananib did not demonstrate a statistically significant improvement in overall survival when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.

The treatment of women with advanced ovarian cancer is set to undergo a substantial transformation, due to an explosion of clinical trials exploring novel treatment options.

A new method to identify protein mutations in cancer cells may help researchers create a personalized vaccine to treat patients with recurrent ovarian cancer.

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

More than one-third of patients with breast or ovarian cancer or a family history of those diseases who also saw a genetic counselor did not pursue genetic testing for BRCA 1 or BRCA 2 mutations.

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

For many years, we in the medical and research communities have tried to use proteins and DNA fragments as disease markers to find cancer early.

Sean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.

The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.

Every patient with a rare but aggressive form of ovarian cancer had tumors with the same type of mutations, suggesting a causative role for the mutations.

The FDA's Oncologic Drugs Advisory Committee voted 11-2 against the accelerated approval of the PARP inhibitor olaparib as a maintenance therapy for women with platinum-sensitive relapsed ovarian cancer with germline BRCA mutations.

Genetic testing limited to BRCA1/2 mutations would have missed 29% of mutations that carry hereditary risk of ovarian cancer, a study using next-generation sequencing showed.

One-quarter of patients with relapsed or refractory BRCA-mutant ovarian cancer attained major objective responses to treatment with the investigational PARP inhibitor veliparib.

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.